This solicitation has closed — responses were due 12 November 2026.
No award notice on SAM.gov yet. Not every award is posted there, so this does not mean it went unawarded.
Email me when the award is announced. One email, when SAM.gov posts the award notice. Not every award is posted there; if none appears within six months we'll tell you and stop. No account needed.
Likely sole source (FedSift estimate from the notice text) — confirm on SAM.gov before investing in a bid
Get new NAICS 334516 solicitations by email
This one has closed. We'll email you when new NAICS 334516 (Analytical Laboratory Instrument Manufacturing) solicitations post — the first email lists what is open right now, then at most once a week, only when something new posts. No account needed; unsubscribe in a click.
Description
Notice of Intent to Sole-Source Requirement The Department of Veterans Affairs, Network Contracting Office (NCO) 10, intends to negotiate a sole source contract under Simplified Acquisition Procedures and the authority of FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. The associated NAICS code for this is 334516, Size Standard is 1,000 employees. Product Service Code (PSC) is Q301. The sole-source contract will be awarded to: VERACYTE, INC UEI: JS7GBP6LCMN6 Description of equipment requirements: The VA Northeast Ohio Healthcare System (VANEOHS) requires continued access to specialized genomic classifier testing used to assess risk of metastasis or metastatic progression in patients with localized or advanced prostate cancer. Decipher prostate testing is a powerful diagnostic and prognostic tool that assesses risk of prostate cancer progression within the next five years post detection, biopsy or surgical removal. The test utilizes a genome-wide transcriptome assay to analyze the expression of 22 genes to generate the Decipher score. Performed on existing tissue samples obtained during biopsy or surgical removal of the prostate, prior to any radiation or hormone therapy. Indicated in localized, N1, or metastatic disease. Provides the Decipher score based on genomic characteristics of the tumor, independent of clinical and pathological factors. The score, ranging between 0 and 1, reflects tumor aggressiveness. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet this requirement. It is the Government's intention to solicit and negotiate with only this source. This notice of intent is not a request for competitive proposals. IAW FAR 5.207 all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. This is not a solicitation or request for offers. No solicitation package is available. Any response to this notice must show clear and convincing evidence that demonstrates the ability to comply with the requirement and that competition would be advantageous to the Government. The Government will not pay for information submitted. A determination not to compete based on responses to this notice is solely within the discretion of the Government. All responses to this intent to sole source must be emailed to Thomas Bellamy: thomas.bellamy@va.gov & Samantha Jarrett: samantha.jarrett@va.gov by 4:00 p.m. EST November 12th, 2026.
Go deeper on this solicitation
FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.
Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.
